drugset / Trial / NCT00198146
Prevention of Diabetes Progression Trial (PDPT)
Phase 2
Completed
40 enrolled
Indiana University
Facet Biotech · collabPescovitz, Mark D., M.D. · collabRoche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the efficacy and safety of daclizumab in preventing the progression of diabetes in children who have just been diagnosed with type I diabetes. Additional purposes of the study are to investigate the amount of drug in the children, how quickly it is eliminated from the blood, and analyze the effect of the drug on the immune reaction to diabetes.
Timeline
- Start
- 2000-07
- Primary completion
- 2007-02-23
- Completion
- 2007-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.